RICHTVXNEWS
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
CNBC · ENGLEWOOD CLIFFS — Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
- CODE
- RT-123F3B
- PUBLISHER
- CNBC
- TOPIC
- Business
- PUBLISHED
- 29 October 2026 · 11:44 UTC
- FIRST SEEN
- 29 October 2026 · 12:15 UTC
- ORIGINAL
- https://www.cnbc.com/2026/10/29/eli-lilly-lly-earnings-q3-2026.html
- SHA-256
- 52e3f5fa40446aae18c5ef3a45d13e34bb11665f78dc41d582fe6d8d49657905
The fingerprint is the SHA-256 of the original link, the headline and the publication time joined by “|”. Anyone can recompute it to confirm the headline and link were not changed here.
Headline and short excerpt from CNBC, taken from its public news feed. The full story and its photos belong to CNBC — read it at the original. RICHTVX NEWS is an independent aggregator and is not affiliated with CNBC. Corrections: legal@richtvx.news.
More from CNBC
European Central Bank keeps key interest rate on hold at 2.5%RT-844FE7 · BUSINESS
Analysis: Kevin Warsh is keeping his options open — and Wall Street guessingRT-97B679 · BUSINESS
Anthropic CEO Dario Amodei charts a new direction for tech philanthropyRT-6379D5 · BUSINESS